{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis%2C+Viral%2C+Human&page=2", "query": { "condition": "Hepatitis, Viral, Human", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis%2C+Viral%2C+Human&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T17:36:17.340Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01625338", "title": "Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "Peg-IFN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 534, "start_date": "2012-06", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2015-11-09", "last_synced_at": "2026-06-26T17:36:17.340Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Bakersfield, California • Colton, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Colton", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625338" }, { "nct_id": "NCT00722332", "title": "Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis B", "Liver Transplantation" ], "interventions": [ { "name": "HepaGam B", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cangene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 9, "start_date": "2008-02", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2013-11-01", "last_synced_at": "2026-06-26T17:36:17.340Z", "location_count": 15, "location_summary": "Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722332" }, { "nct_id": "NCT00391482", "title": "Study to Reduce Intravenous Exposures (STRIVE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hepatitis C", "HIV Infections" ], "interventions": [ { "name": "Peer Mentoring Intervention for HCV-Infected IDUs", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Institute on Drug Abuse (NIDA)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 750, "start_date": "2002-06", "completion_date": "2005-02", "has_results": false, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-06-26T17:36:17.340Z", "location_count": 3, "location_summary": "Baltimore, Maryland • New York, New York • Seattle, Washington", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00391482" }, { "nct_id": "NCT00376259", "title": "Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "telbivudine", "type": "DRUG" }, { "name": "adefovir dipivoxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 43, "start_date": "2007-01", "completion_date": null, "has_results": true, "last_update_posted_date": "2011-06-30", "last_synced_at": "2026-06-26T17:36:17.340Z", "location_count": 2, "location_summary": "San Diego, California • San Mateo, California", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Mateo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376259" }, { "nct_id": "NCT00275652", "title": "A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis B", "Cirrhosis" ], "interventions": [ { "name": "LdT (Telbivudine) and lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2004-06", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2011-03-23", "last_synced_at": "2026-06-26T17:36:17.340Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00275652" }, { "nct_id": "NCT01728324", "title": "Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "BI 207127-placebo: 8-week treatment", "type": "DRUG" }, { "name": "Ribavirin: 24-week treatment", "type": "DRUG" }, { "name": "BI 207127: 24-week treatment", "type": "DRUG" }, { "name": "Faldaprevir: 24-week treatment", "type": "DRUG" }, { "name": "Ribavirin-placebo: 8-week treatment", "type": "DRUG" }, { "name": "Faldaprevir-placebo: 8-week treatment", "type": "DRUG" }, { "name": "Faldaprevir: 16-week treatment", "type": "DRUG" }, { "name": "Ribavirin: 16-week treatment", "type": "DRUG" }, { "name": "RBV: 24-week treatment", "type": "DRUG" }, { "name": "BI 207127: 16-week treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 496, "start_date": "2012-11", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-02-12", "last_synced_at": "2026-06-26T17:36:17.340Z", "location_count": 31, "location_summary": "North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01728324" }, { "nct_id": "NCT00439959", "title": "Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C, Chronic", "Hepatitis C" ], "interventions": [ { "name": "GSK625433/placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2006-10", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2012-06-04", "last_synced_at": "2026-06-26T17:36:17.340Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00439959" }, { "nct_id": "NCT01356160", "title": "GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin tablet", "type": "DRUG" }, { "name": "GS-9451 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 351, "start_date": "2011-07", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-06-26T17:36:17.340Z", "location_count": 21, "location_summary": "Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01356160" }, { "nct_id": "NCT00867243", "title": "Prediction of Hepatitis C Recurrence in Liver Transplant Recipients", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Complication of Transplanted Liver", "Hepatitis C, Chronic" ], "interventions": [], "intervention_types": [], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2005-10", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2013-06-11", "last_synced_at": "2026-06-26T17:36:17.340Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00867243" }, { "nct_id": "NCT06907290", "title": "A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Chronic Hepatitis D Infection" ], "interventions": [ { "name": "Brelovitug 300 mg", "type": "DRUG" }, { "name": "Brelovitug 900 mg", "type": "DRUG" }, { "name": "Delayed Treatment with Brelovitug 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirum Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-03-25", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-06-26T17:36:17.340Z", "location_count": 15, "location_summary": "Garden Grove, California • Huntington Beach, California • Long Beach, California + 9 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06907290" } ] }